Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tvardi Therapeutics (TVRD) Non-Current Assets (2016 - 2025)

Tvardi Therapeutics' Non-Current Assets history spans 13 years, with the latest figure at $535000.0 for Q4 2025.

  • On a quarterly basis, Non-Current Assets fell 84.77% to $535000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $5.2 million, a 78.54% decrease, with the full-year FY2025 number at $535000.0, down 84.77% from a year prior.
  • Non-Current Assets hit $535000.0 in Q4 2025 for Tvardi Therapeutics, down from $578000.0 in the prior quarter.
  • Over the last five years, Non-Current Assets for TVRD hit a ceiling of $73.8 million in Q4 2021 and a floor of $535000.0 in Q4 2025.
  • Historically, Non-Current Assets has averaged $25.2 million across 5 years, with a median of $10.6 million in 2023.
  • Biggest five-year swings in Non-Current Assets: skyrocketed 274.8% in 2021 and later crashed 92.82% in 2025.
  • Tracing TVRD's Non-Current Assets over 5 years: stood at $73.8 million in 2021, then plummeted by 81.93% to $13.3 million in 2022, then dropped by 27.32% to $9.7 million in 2023, then tumbled by 63.73% to $3.5 million in 2024, then tumbled by 84.77% to $535000.0 in 2025.
  • Business Quant data shows Non-Current Assets for TVRD at $535000.0 in Q4 2025, $578000.0 in Q3 2025, and $620000.0 in Q2 2025.